新辅助放化疗与围手术期化疗联合或不联合免疫治疗在可切除食管腺癌中的比较
该回顾性队列研究纳入811例可切除食管或胃食管交界腺癌患者,比较诱导放化疗与围手术期化疗联合或不联合免疫治疗的病理反应和早期生存。放化疗组病理完全缓解率和病理淋巴结阴性率更高,但围手术期化疗组2年无事件生存率更优,2年总生存无统计学差异。
要点
- 放化疗组病理完全缓解率23% vs 化疗组14%,病理淋巴结阴性率61% vs 46%。
- 围手术期化疗组2年无事件生存率66% vs 放化疗组53%,调整后HR 0.53。
- 两组2年总生存无统计学差异,R0切除率均为96%。
核心结论
- 两种诱导策略围手术期结局均良好,放化疗病理完全缓解率更高,但围手术期化疗联合或不联合免疫治疗与更长的早期无事件生存相关。
主要发现
- 放化疗组650例(80%),化疗联合或不联合免疫治疗组161例(20%),中位随访29.9个月。
- 放化疗组病理完全缓解率23% vs 14%,病理淋巴结阴性率61% vs 46%,调整后均P < .001。
- 两组R0切除率均为96%。
- 化疗联合或不联合免疫治疗组2年无事件生存率66% vs 53%,调整后HR 0.53,P = .007。
- 两组2年总生存无统计学差异;多变量分析中围手术期化疗联合或不联合免疫治疗和病理完全缓解与更长无事件生存独立相关。
临床怎么用
- 对于可切除食管腺癌,两种诱导策略均可采用,围手术期化疗联合或不联合免疫治疗与更优的早期无事件生存相关,放化疗与更高病理完全缓解率相关。
局限性
- 围手术期化疗联合或不联合免疫治疗与更长无事件生存的关联在倾向性评分匹配和90天landmark分析中减弱,需要更长随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to compare pathologic responses, perioperative outcomes, and early survival between induction chemoradiotherapy and perioperative chemotherapy with or without immunotherapy in patients with resectable esophageal adenocarcinoma. METHODS: Using our prospectively maintained institutional database, we retrospectively identified adult patients with resectable, locally advanced esophageal or gastroesophageal junction adenocarcinoma who underwent esophagectomy from January 2013 to October 2024 after induction chemoradiotherapy or perioperative chemotherapy with or without immunotherapy. The primary outcome was rate of pathologic complete response. Secondary outcomes included rate of microscopically margin-negative resection, rate of pathologic node-negative status, and perioperative morbidity. Event-free survival and overall survival were estimated using Kaplan-Meier methods and were evaluated using Cox regression. RESULTS: Of 811 patients, 650 (80%) received chemoradiotherapy, and 161 (20%) received chemotherapy with or without immunotherapy. Median follow-up was 29.9 months. Chemoradiotherapy was associated with greater rates of pathologic complete response (23% vs 14%) and pathologic node-negative status (61% vs 46%; both P < .001 after adjustment). The rate of microscopically margin-negative resection was 96% in both groups. Two-year event-free survival was greater in the chemotherapy with or without immunotherapy group (66% vs 53%; adjusted hazard ratio, 0.53; P = .007). Two-year overall survival was not statistically different between groups. On multivariable analysis, perioperative chemotherapy with or without immunotherapy and pathologic complete response were independently associated with longer event-free survival. CONCLUSIONS: Both induction strategies achieved excellent perioperative outcomes. Despite greater rates of pathologic complete response with chemoradiotherapy, perioperative chemotherapy with or without immunotherapy was associated with longer early event-free survival. This association was attenuated in propensity score-matched and 90-day landmark analyses. Longer follow-up is warranted.
引用
- Alkaaki A, Zheng N, Toumbacaris N, et al. Neoadjuvant chemoradiotherapy versus perioperative chemotherapy with or without immunotherapy in resectable esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2026. PMID: 42777942. doi:10.1016/j.jtcvs.2026.09.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。